GRK2 regulates GLP-1R-mediated early phase insulin secretion in vivo

Area of Science:

• Endocrinology
• Molecular Biology
• Cell Signaling

Background:

• Insulin secretion by pancreatic β-cells is crucial for glucose homeostasis.
• Incretin hormones like glucagon-like peptide-1 (GLP-1) enhance insulin release via GLP-1 receptors (GLP-1R).
• The role of G protein-coupled receptor kinase 2 (GRK2) in insulin secretion and incretin action was previously unexamined.

Purpose of the Study:

• To investigate the physiological role of GRK2 in regulating insulin secretion.
• To determine if GRK2 modulates incretin hormone actions in vivo.
• To explore the potential therapeutic implications of targeting GRK2 for diabetes.

Main Methods:

• Utilized GRK2 hemizygous mice (GRK2+/-), isolated pancreatic islets, and β-cell lines.
• Administered feeding, oral glucose, or GLP-1R agonists to assess insulin release.
• Employed nanoBRET assays in β-cell lines to study receptor-GRK2 interactions.

Main Results:

• Reduced GRK2 levels in GRK2+/- mice enhanced early-phase insulin secretion in response to feeding, glucose gavage, or GLP-1R agonists.
• Intraperitoneal glucose-induced insulin release was unaffected by GRK2 reduction.
• GRK2 association with GLP-1R upon stimulation was observed, with GRK2 required for β-arrestin recruitment.

Conclusions:

• GRK2 acts as a significant negative modulator of GLP-1R-mediated insulin secretion.
• Targeting GRK2 may specifically enhance early-phase β-cell insulin secretion.
• GRK2-interfering strategies hold potential therapeutic value for managing glucose metabolism.